- Home
- PTGX vs TSLX Comparison
PTGX vs TSLX Comparison
Compare PTGX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTGX | TSLX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 2.2B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PTGX | TSLX |
|---|---|---|
| Price | $89.42 | $21.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $90.56 | $23.50 |
| AVG Volume (30 Days) | ★ 982.6K | 457.1K |
| Earning Date | 11-06-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 9.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.72 | ★ 2.04 |
| Revenue | $209,217,000.00 | ★ $464,512,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $288.98 | N/A |
| P/E Ratio | $123.27 | ★ $10.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.70 | $18.58 |
| 52 Week High | $96.54 | $25.17 |
Technical Indicators
Market Signals| Indicator | PTGX | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 47.70 |
| Support Level | $84.11 | $21.18 |
| Resistance Level | $90.00 | $21.58 |
| Average True Range (ATR) | 3.27 | 0.29 |
| MACD | -0.65 | -0.08 |
| Stochastic Oscillator | 41.92 | 31.72 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.